Welcome to CDC stacks | Large-scale automatic extraction of side effects associated with targeted anticancer drugs from full-text oncological articles - 34602 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
Clear All Simple Search
Advanced Search
Large-scale automatic extraction of side effects associated with targeted anticancer drugs from full-text oncological articles
Filetype[PDF-1.19 MB]

  • Pubmed ID:
  • Pubmed Central ID:
  • Description:
    Targeted anticancer drugs such as imatinib, trastuzumab and erlotinib dramatically improved treatment outcomes in cancer patients, however, these innovative agents are often associated with unexpected side effects. The pathophysiological mechanisms underlying these side effects are not well understood. The availability of a comprehensive knowledge base of side effects associated with targeted anticancer drugs has the potential to illuminate complex pathways underlying toxicities induced by these innovative drugs. While side effect association knowledge for targeted drugs exists in multiple heterogeneous data sources, published full-text oncological articles represent an important source of pivotal, investigational, and even failed trials in a variety of patient populations. In this study, we present an automatic process to extract targeted anticancer drug-associated side effects (drug-SE pairs) from a large number of high profile full-text oncological articles. We downloaded 13,855 full-text articles from the Journal of Oncology (JCO) published between 1983 and 2013. We developed text classification, relationship extraction, signaling filtering, and signal prioritization algorithms to extract drug-SE pairs from downloaded articles. We extracted a total of 26,264 drug-SE pairs with an average precision of 0.405, a recall of 0.899, and an F1 score of 0.465. We show that side effect knowledge from JCO articles is largely complementary to that from the US Food and Drug Administration (FDA) drug labels. Through integrative correlation analysis, we show that targeted drug-associated side effects positively correlate with their gene targets and disease indications. In conclusion, this unique database that we built from a large number of high-profile oncological articles could facilitate the development of computational models to understand toxic effects associated with targeted anticancer drugs.

  • Document Type:
  • Collection(s):
  • Funding:
    DP2 HD084068/HD/NICHD NIH HHS/United States
    DP2HD084068/DP/NCCDPHP CDC HHS/United States
    R25 CA094186/CA/NCI NIH HHS/United States
    R25CA094186-06/CA/NCI NIH HHS/United States
    UL1 RR024989/RR/NCRR NIH HHS/United States
    UL1 TR000439/TR/NCATS NIH HHS/United States
No Related Documents.
You May Also Like: